FDA’s budget proposal includes a set of policy priorities, including a move to make pediatric priority review vouchers permanent. The budget plan also signals continued pressure on agency advisory committee participation. The proposal arrives as stakeholders continue to debate how voucher incentives affect development timelines and patenting strategy for pediatric drug candidates. For sponsors, the prospect of permanence would increase predictability around the regulatory economics of pediatric planning. Industry groups will likely respond by assessing whether the policy changes alter development and filing strategies across pediatric oncology and rare disease programs.